Lynparza (olaparib)

Platinum-Sensitive Relapsed Setting

Study 19: Long term efficacy in platinum-sensitive relapsed BRCAm and non-BRCAm patients13

Study 19 investigated women with PSR ovarian cancer regardless of BRCA status, LYNPARZA, compared to placebo, was shown to:

  • Significantly reduce the risk of death or disease progression by 65% (HR 0.35; 95% CI=0.25-0.49; P<0.0001)13
  • Improve median PFS by 3.6 months (8.4 vs. 4.8 months)13

Study 19: Investigator-assessed progression-free survival in PSR ovarian cancer patients13

Adapted from Ledermann, J, et al. 2014

Study 19: PFS in BRCAm patients13

Study 19: PFS in non-BRCAm patients13

Adapted from Ledermann, J, et al. 2014

Data from a pre-planned subgroup retrospective analysis by BRCAm status of the pivotal phase II study (Study 19). Data cut-off: 30 June 2010.17

LYNPARZA (capsules) is the only PARPi that has more than 6 years’ follow-up data from Study 19, with 11% of PSR ovarian cancer patients remaining on LYNPARZA after 6 years.6,18


Study 19: Number of patients receiving LYNPARZA or placebo by years of treatment for the overall population18 Adapted from Friedlander, M. et al. 2018

 

Adapted from Friedlander, M. et al. 2018

SOLO-2: Provides confirmatory evidence of the effect of LYNPARZA tablets in gBRCAm patients14

  • Significantly reduce risk of disease progression or death by 70% (HR = 0.30; 95% CI = 0.22-0.41; p<0.0001)14
  • Improve median PFS by 13.6 months (19.1 months versus 5.5 months)14

In a subsequent Phase III clinical study, SOLO-2, which investigated women with gBRCAm PSR ovarian cancer, LYNPARZA (tablets), compared to placebo, was shown to:



SOLO-2: Investigator-assessed progression-free survival in gBRCAm patients14

Adapted from Pujade-Lauraine E, et al. 2017.